// < ![CDATA[ yahooBuzzArticleHeadline=ImmunoCellular+Therapeutics+Delivers+on+Key+Milestones+%28OTC%3AIMUC%29; // ]]> ImmunoCellular just announced their lead monoclonal antibody product candidates ICT-109 had positive result in their lead study of detecting cancerous tissues. The results were statically significant suggesting that this antibody can determine if tissues are cancerous or non-cancerous in plasma and serum study sets. These results from the study lead IMUC to believe that this ICT-109 molecule can play an important role in early cancer detection which is absolutely critical in for a most efficient treatment. This will be the second milestone of four that Dr Singh, Ph.D., president and CEO of IMUC, has delivered on time. Singh says IMUC will conduct additional studies testing ICT-109 with other markers to design a robust assay that hopefully will become wildly adopted or the standard in early cancer detection. They will be seeking a partner that specialized in commercial development this type of approach/diagnostic tool. The next milestone that Dr. Singh is scheduled to deliver on is the ...